Funding for this research was provided by:
National Cancer Institute (P30-CA008748, K24-CA160653, P50-CA92629, P30-CA054174, R01-CA179115)
Congressionally Directed Medical Research Programs (W81XWH-15-1-0441)
Text and Data Mining valid from 2019-10-15
Received: 14 November 2018
Accepted: 20 September 2019
First Online: 15 October 2019
Ethics approval and consent to participate
: Collection of all data and materials used in this report were approved by University of Texas Health Science Center of San Antonio Institutional Review Board (IRB), Memorial Sloan Kettering Cancer Center IRB, Mayo Clinic IRB, University of California San Francisco Human Research Protection Program Committee on Human Research, Cleveland Clinic IRB and Human Research Protections, Sunnybrook Health Sciences Centre Research Ethics Board, VA Caribbean Healthcare System IRB, VA Durham Subcommittee on Research Safety, San Raffaele Hospital IRB, and University Hospital Zurich IRB. Patient consent was waived as only retrospective de-identified data were used.
: Not applicable.
: AJV has a patent on a panel of markers to detect prostate cancer and receives royalties from the sale of the test; MWK is a consultant for Stratify Genomics. All other authors declare that they have no financial conflict of interest.